Key Takeaways
- K.N.A. Inter Pharma and Diamond Biotechnology have established a joint venture to create Thailand’s first medical device manufacturing plant for aesthetics.
- The THB 3 billion investment aims to position Thailand as a leading ‘Medical Hub’ in Asia.
- The facility will start construction in January 2026 and produce FDA-compliant medical instruments set for international export, primarily targeting Asia and the Middle East.
Partnership Announcement
K.N.A. Inter Pharma Co., Ltd. has partnered with Diamond Biotechnology Co., Ltd. to create a groundbreaking medical device manufacturing plant in Pathum Thani, Thailand. This collaboration represents an investment exceeding THB 3 billion and aims to elevate Thailand as an integrated “Medical Hub,” enhancing the country’s standing in the aesthetic and medical sectors.
Mr. Nadrincha Pathan, President of K.N.A. Inter Pharma, emphasized the significance of this partnership as a milestone in establishing Thailand as a leader in aesthetic innovation. He acknowledged Diamond Biotechnology’s expertise in advanced biomedical technologies and viewed this venture as a means to improve the quality of domestically produced aesthetic medical devices, reducing Thailand’s dependency on imports.
During a press briefing, Dr. Aaron Shia-Hsien Hsia, Chairman of Diamond Biotechnology, expressed confidence in Thailand’s market potential. He cited the country’s skilled medical professionals, growth in aesthetic medicine, and favorable investment policies as key factors for choosing Thailand as their production base in Asia. This decision is also fueled by a strong, three-year partnership with K.N.A., which is expected to facilitate market expansion across Asian and Middle Eastern regions.
The manufacturing facility, under a joint venture, will initially carry a capital of THB 500 million, with an additional THB 2 billion designated for infrastructure, machinery, research and development, and four patented aesthetic products. Construction is set to begin on January 1, 2026, with production anticipated to start in 2027. Initial efforts will focus on exports to international markets, especially China, as well as internal marketing in Thailand and select Southeast Asian countries.
Dr. Rassapoom Sumaetheiwit, a board-certified dermatologist and key partner in the project, highlighted the growing market for aesthetic medicine in Thailand. He stated that the venture offers an opportunity to introduce cutting-edge technology and raise treatment standards in local clinics while minimizing reliance on imports and creating job opportunities within the country.
Additionally, Dr. Rassapoom will advise on product development tailored to aesthetic medical needs. The project is supported by a team of reputable medical professionals who will strengthen the venture’s research, production, and clinical application capabilities, ensuring that both domestic and international demands are efficiently met.
The content above is a summary. For more details, see the source article.
